As revolutionary new weight-loss drugs turn consumers off ultraprocessed foods, the industry is on the hunt for new products.

KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE).

As GLP-1 drugs like Ozempic soar in popularity for weight loss, this film follows three people on their own GLP-1 journeys and explores how decades of diet culture and society’s relentless pursuit of ...

Ozempic, a weight loss drug that has exploded in use across America, has joined a list of treatments that started with benign intentions and evolved into a reflection of the modern weight loss and ...

Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...

Real-world data show reduction in use of urate-lowering therapy among people with type 2 diabetes using SGLT2 inhibitors.

Cardiometabolic disease biotech NeuroBo Pharmaceuticals is shaking up its corporate image with a complete rebrand. | ...

Inno Supps’ Trim Biome™ GLP-1 is designed to support the body’s natural production of GLP-1 through a unique blend of ...

Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GIP/GLP-1) ...

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...